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ThObjective: We sought to investigate a placement of a percutaneous low-profile
prosthetic valve constructed of small intestinal submucosa in the pulmonary position
in a swine model.
Methods: Twelve female farm pigs were stented at the native pulmonary valve to
induce pulmonary insufficiency. Once right ventricular dilation occurred, the small
intestinal submucosa valve was implanted. The pigs were followed up with trans-
thoracic echocardiographic Doppler scanning. One animal died of heart failure
before valve replacement. Animals were euthanized at 1 day, 1 month, 3 months, 6
months, and 12 months after valve implantation.
Results: The small intestinal submucosa pulmonary valve showed effective reversal
of pulmonary regurgitation. There were no misplacements during deployment.
There were no embolizations. One-year echocardiographic follow-up showed min-
imal regurgitation and no stenosis for a valve/vessel ratio of 0.78 or greater.
Histologic examination demonstrated intensive remodeling of the small intestinal
submucosal valve. Within 1 month, the surface was covered by endothelium, and
fibroblasts invaded the interior. Over the following months, the small intestinal
submucosal valve remodeled without apparent graft rejection.
Conclusion: The small intestinal submucosa valve has the potential for graft lon-
gevity without the need for anticoagulation or immunosuppression. Histologic
remodeling of the valve tissue provides a replacement capable of resembling a
native valve that can be placed percutaneously with low-profile delivery systems.
Surgical replacement of cardiac valves remains the cornerstone therapy forend-stage valvular disease and substantially improves its natural history.1There are 2 types of valve prostheses: mechanical and biologic. The mechan-
ical valves are associated with substantial risks of thromboembolism and hemolysis;
the biologic valves tend to become dysfunctional in a relatively short time because
of tissue deterioration.2-5 Furthermore, the current clinically used tissue valves are
nonviable; they lack the potential to remodel, and therefore their durability is
limited. Porcine small intestinal submucosa (SIS) is an acellular matrix prepared
from the jejunum and is used as a xenograft material because it induces variable
degrees of tissue-specific remodeling in the organ or tissue into which it is
placed.6-12 It is mostly composed of type I collagen, although it has some type III
and type IV collagen in addition to other extracellular matrix molecules, such as
fibronectin, hyaluronic acid, chondroitin sulfate A and B, heparin, and heparin
sulfate, and some growth factors, such as basic fibroblast growth factor, transform-
ing growth factor , and vascular endothelial growth factor. Recently, Matheny and
colleagues13 used single-layer porcine SIS as a substitute for mature pulmonary
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cine SIS tissue mounted on a self-expandable stent might
result in remodeled SIS, with similar properties and behav-
ior as native valvular tissue, when implanted near a native
cardiac valve.
Therefore, we investigated the percutaneous placement
of an SIS valve in 12 farm pigs with induced right ventric-
ular failure. The rationale for this approach was to document
the behavior of such an SIS-based valve by echocardiogra-
phy, postmortem extracorporeal cycling studies, and histo-
pathology, enabling further investigation toward a new ther-
apeutic valve based on SIS material in the future.
Methods
This investigation was approved by the University of Illinois at
Chicago’s Animal Care Committee and was in compliance with
the 1996 “Guide for the Care and Use of Laboratory Animals” and
the Animal Welfare Act.
Self-Expandable Valve
The pulmonary valve prostheses were constructed of square stents
with 4 barbs (Cook Inc, Bloomington, Ind) and a hydrated sheet of
Figure 1. A, Self-expanding square stent. B, SIS mater
model during extracorporeal cycling studies at systoleSIS (Cook Biotech, Lafayette, Ind). In this study square stents
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previously described.7 The square stent is a simply constructed,
self-expanding device that has 4 corners bent into spring-like coils
to reduce stress and metal fatigue. The wire ends are extended 1
mm over the stent frame, forming barbs on opposing stent corners
to provide anchors for the stent during placement. Two more
anchoring barbs are added by attaching a wire to the contralateral
side of the stent frame. Two triangular pieces of SIS were sutured
with 7-0 Prolene monofilament (Ethicon, Inc, Somerville, NJ) to
the stent frame to form the valve. The layer of SIS sutured to the
metal frame had a flap about 2 mm wide, extending beyond the
frame (Figure 1).7,14 All valves were 17 mm in diameter. After
construction, the valves were lyophilized and gas sterilized. The
lyophilized SIS sheet was 100 to 120 m thick. The valves were
then folded and front loaded into an 8F Teflon sheath 80 cm long
(Cook Inc) and delivered coaxially.7,14 Extracorporeal cycling
studies were conducted by the manufacturer in advance of this
study.
Preparation of Animals With Right
Ventricular Failure
Twelve female farm pigs weighing 8 to 18 kg received sedation
with 0.05 mg/kg intramuscular atropine, 4.4 mg/kg intravenous
ttached to stent. C, SIS valve. D and E, SIS valve tube
and diastole (E).ial a
(D)tetrazol, and 2.2 mg/kg xylazine. The animals were endotracheally
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maintained at stage III, planes 1 to 2, with 2% to 3% isoflurane
(Iso-thesia; Burns Veterinary Supply, Rockville Center, NY) in
oxygen. The animals then underwent cardiac catheterization for
stenting of the native pulmonary valve. Digital fluoroscopic im-
ages were obtained and stored with an OEC-9600 C-arm cardiac
mobile system (GE Medical Systems, Waukesha, Wis). The native
pulmonary valve, the distal part of the right ventricular outflow
tract, and the proximal third of the main pulmonary artery (PA)
were covered with 2 to 3 metallic stents (Cordis Corp, Miami
Lakes, Fla). The stents were mounted on a 14.0 mm  3.0 cm, 7.0
mm  2.0 mm BIB-balloon (NuMed, Hopkinton, NY) and de-
ployed under simultaneous digital fluoroscopy and transthoracic
echocardiographic (TTE) guidance. Moderate-to-severe pulmo-
nary regurgitation was documented by means of color flow Dopp-
ler scanning in all animals. The animals were returned to their
community cages for a 2- to 4-week period until significant right
ventricular dilatation was documented with TTE.
Percutaneous Valve Implantation
The animals underwent percutaneous access of the right internal
jugular vein after achievement of general anesthesia. By using a
multipurpose catheter, the stented native pulmonary valve was
crossed, and an extrastiff Amplatz wire (AGA Medical Corp,
Golden Valley, Md) was advanced to one of the distal PA
branches. The multipurpose catheter was exchanged for the 8F
delivery system, which was advanced over the guide wire into the
main PA just distal to the stented valve. The valve was deployed
under fluoroscopic and TTE guidance. After deployment, the valve
orifice was not crossed to prevent any dislodgement, and the guide
wire was pulled out. The intracardiac echocardiographic probe
(AcuNav; Acuson, Mountain View, Calif) was advanced to the
mid–superior vena cava to best visualize the newly implanted
valve. The pigs received 100 U/kg heparin at the beginning of the
procedure, and it was not reversed at the end of the procedure.
Serial Follow-up
All animals were started on 325 mg/d oral aspirin, but no antico-
agulants were used. The pigs underwent weekly TTE under seda-
tion for the first 4 weeks after valve implantation. Echocardio-
grams were obtained with an Acuson Sequoia (Acuson) and a
5-MHz transducer, and the images were digitally stored, as well as
videotape recorded. Four weeks after implantation, serial TTEs
were obtained every 2 weeks until animal death. The animals were
euthanized in the following order: 1 animal at both 24 hours and at
1 month and 3 animals at each of the 3-month, 6-month, and 1-year
end points. Euthanasia was performed after achievement of general
anesthesia with 100 mg/kg sodium pentobarbital. Before death, all
animals received 50,000 U of heparin intravenously to prevent any
postmortem clot formation and underwent diagnostic cardiac cath-
eterization, angiography, and intracardiac echocardiography.
Histology and Flow Evaluation
Immediately after death, the distal right ventricular outflow
tract–PA bifurcation was carefully dissected and removed. The
vessel was rinsed in saline and placed in a container with 0.9%
sterile iced saline with gentamicin. The container was then placed
on ice and sent to the histology laboratory. Before fixation and
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quired. Unfixed valves were placed in tubing of appropriate size to
hold the valve in place. Blood flow was simulated with an electric
pump circulating 0.9% saline solution through the tubing contain-
ing the valve. An endoscope was placed close enough to the valve
to capture video images of its function. Afterward, the valves were
placed in 10% neutral-buffered formalin and allowed to fix for 24
to 48 hours. After fixation, the vessels were dehydrated and em-
bedded in methylmethacrylate plastic. After polymerization, the
samples were cut on a plane perpendicular to the orifice of the
valve. Longitudinal thick sections (approximately 50 m) were cut
with a rotary saw microtome and stained with hematoxylin and
eosin. For immunohistochemical examination, sections of tissue
were deparaffinized and rehydrated. Antigen retrieval was accom-
plished by an antigen retrieval solution (Dako Cytomation, Carpin-
teria, Calif). Endogenous peroxidase was blocked for 15 minutes
with 3% hydrogen peroxide. Nonspecific immunoglobulin binding
was blocked by incubation of slides for 10 minutes with a protein-
blocking agent (Dako Cytomation) before application of the pri-
mary antibodies (all Dako Cytomation). Vimentin immunostain
was used to document mesenchymal differentiation, desmin and
smooth muscle actin were used for muscle cell differentiation, and
von Willebrand factor VIII and CD31 were used for angioforma-
tive differentiation. A labeled streptavidin-biotin-peroxidase com-
plex system (Dako Cytomation) was used to visualize all immune
reactions. The immunoreaction was visualized with 3,3=-diamino-
benzidine substrate (Dako Cytomation). Sections were counter-
stained with Mayer hematoxylin. Positive immunohistochemical
controls included lymph nodes and arteries from normal swine to
which the appropriate antisera were added. For negative controls,
the primary antibodies were replaced with homologous nonim-
mune sera.15 An independent board-certified pathologist experi-
enced in the evaluation of chronically implanted vascular stents
performed qualitative histopathologic evaluation of the stented
vessels. Slides were evaluated for remodeling of the valve material
and to assess potential adverse effects, with particular attention to
the interface between the implant and the vessel wall, as well as
signs of graft rejection.
Results
All 12 animals had their pulmonary valves stented success-
fully. One animal died of heart failure before valve implan-
tation. The SIS valve was percutaneously implanted in 11
pigs (median weight, 23.6 kg; range, 17.5-34.4 kg). In 10
animals the valves were implanted just distal to the distal
stent within the main PA. In 1 animal expected to survive
for 1 year, the valve was implanted at the origin of the right
PA to minimize the mismatching effects of somatic growth
between the valve and the vessel wall. There were no major
clinical complications from any of the procedures, and none
were observed during the follow-up period (ie, valve throm-
bosis and infective endocarditis).
One Day
Echocardiographic results. The presence of moderatetricuspid regurgitation (TR) was observed after stent im-
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Evolving Technology Ruiz et alFigure 2. A, SIS valve 1 day after implantation, hematoxylin and eosin staining. Acellular SIS collagen fibers were
separated, resulting in marked leaflet thickening by serum, blood, minimal fibrin, and a few platelets. B, Three
months after implantation. Early remodeling shows thin neointima coating the valvular surface. C, Six months after
implantation. Ongoing remodeling demonstrates a continuous epithelial coating and host connective tissue inside
the valve interior. D, Twelve months after implantation. Advanced remodeling showing differentiated epithelial
lining; fibroblasts and smooth muscle cells are shown in the interior. E, Native pulmonary leaflet, hematoxylin and
eosin staining. F-H, SIS valve 12 months after implantation, antibody staining: F, subendothelial von Willebrand
factor VIII; G, interstitial smooth muscle cells; H, connective tissue vimentin.
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m/s. After valve implantation, the TR improved to trace, and
the TR velocity decreased to 1.40 m/s. There was a mod-
erate degree of perivalvular leak, but there was no valvular
regurgitation. Perivalvular leak was observed in all
implants.
Gross anatomy. The valve appeared well anchored to
the PA. The implant was attached to the vessel wall by the
hooks; however, there was no tissue attachment between the
leaflets and the arterial wall.
Histopathology. The valve leaflets were 17 mm in
length, and the diameter of the main PA was 13 mm,
resulting in a valve/PA ratio of 1.3. There were no infiltrat-
ing host cells. The SIS collagen fibers were separated,
resulting in marked edema of the leaflets by means of
infiltration of serum, blood cells, minimal fibrin, and a few
platelets. There were no signs of graft rejection (Figure 2).
One Month
Echocardiographic results. A trace of TR was still
present, and the TR average velocity was 1.08 m/s. There
was a trivial central jet of pulmonary insufficiency deter-
mined by means of color flow Doppler scanning, and the
perivalvular leak was still present in 3 of the 10 animals,
although it was significantly decreased.
Gross anatomy. The video recording of the prosthetic
valve within the PA in a pump simulator revealed very
pliable leaflets with complete coaptation. The base of the
leaflets was firmly adhered to the vessel wall. The valve/PA
ratio was 1.02.
Histopathology. The leaflets were infiltrated with host
fibroblasts and capillaries, but the SIS was still visible. A
thin neointima covered large portions of the leaflet. Endo-
thelium partially covered most of the leaflet, some areas
only sporadically. There were few lymphocytes and plasma
cells, which were not consistent with graft rejection in
number and appearance.
Three Months
Echocardiographic results. There was no change in the
amount of TR, and the mean velocity was 1.36 m/s. There
was still a trivial central jet pulmonary regurgitation deter-
mined by color flow Doppler scanning that had not changed
from the 1-month follow-up. There were no perivalvular
leaks in any of the 9 animals at 3 months.
Gross anatomy. The valve/PA ratio was 0.88. The valve
was well anchored to the PA. The prosthetic valve was well
incorporated and firmly adhered to the vessel wall. There
was a minimal progression of leaflet stiffening noted by in
vitro video recording, with an apparent increase in leaflet
thickness but with complete coaptation.
Histopathology. The valves were firmly adhered to the
vessel wall, and the leaflets were slightly shorter (mean,
The Journal of Thoracic a15.6 mm). The base of the leaflets had a thin coating of
neointima (usually 20 m thick), which extended to the
remainder of the leaflet as a neointimal coating 1 to 2 cells
thick. In the middle the leaflets were approximately 200 m
thick and contained mostly dense collagen fibers, with few
capillaries and few infiltrating host cells (Figure 2). Endo-
thelium was present but occasionally sporadic. There were
no signs of graft rejection.
Six Months
Echocardiographic results. There was essentially un-
changed TR, with a mean velocity of 1.49 m/s. There was
no change in the amount of pulmonary regurgitation in any
of the animals, and there were no perivalvular leaks.
Gross anatomy. The valve/PA ratio was 0.78. All the
valves appeared well anchored to the PA. There was further
increase in stiffening and thickness of the leaflets, but they
still had complete coaptation.
Histopathology. The leaflets were slightly shorter
(mean, 14.4 mm) and thicker at the base and in the middle
of the leaflet. Neointima was usually 50 to 150 m thick at
the base and tapered toward the tip of the leaflet. In the
middle the leaflets were usually 200 to 400 m thick (one
up to 1200 m thick) and fully infiltrated with spindle-
shaped host cells, capillaries, and arterioles and covered
with neointima 10 to 20 m thick and endothelium (Figure
2). There were no signs of graft rejection.
One Year
Echocardiographic results. There was an increase in
the amount of TR caused by dilatation of the right ventricle
that progressed from the 10- and 11-month follow-ups in the
2 animals that had valves implanted in the main PA. By the
12th month, both animals had wide-open pulmonary regur-
gitation, and in both animals the valve stent was noted to be
broken and separated on one side from the PA wall. The
animal that had the valve implanted in the right PA had
trivial pulmonary regurgitation through the valve, and there
was no gradient across the valve. All 3 animals had signif-
icant pericardial and pleural effusion.
Gross anatomy. At autopsy, the 2 animals with im-
planted valves in the main PA had a dilated right ventricle
and right atrium, with large pericardial and pleural effusion.
The valve/PA ratio was 0.48. In one animal a fragment of
the stent was noted protruding through the main PA wall.
The prosthetic valves implanted in the main PA were both
fractured and separated on one side from the PA wall. The
valve leaflets were torn on one side, and there was a sig-
nificant mismatch between the valve stent frame diameter
(17 mm) and the size of the main PA (34.8 mm) at the time
of death. The animal that had the valve implanted at the
origin of the right PA had no fractures of the stent, and the
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noted.
Histopathology. The valve leaflets ranged from 200 to
1200 m thick and measured 9 mm. In the middle the
leaflets were fully infiltrated with fibroblasts, capillaries,
arterioles, and a few scattered lymphocytes and covered
with neointima 10 to 20 m thick and endothelium (Figure
2). A few thick, dense collagen fibers were present in the
core of the leaflet. Immunohistochemically, the core of the
leaflet was phenotypically fibroblastic cells intermixed with
dense collagen and capillaries. A layer of spindle-shaped
cells that were phenotypically similar to smooth muscle
cells surrounded the core (Figure 2). Inflammation was
mostly absent. By comparison, native pulmonary leaflets
(Figure 2) were approximately 5 mm long and ranged from
1 mm thick at the base to approximately 100 to 300 m over
most of its length. The valve was composed of dense
collagenous connective tissue and elastic fibers forming
bands under the endothelium on both surfaces. The central
surface of the valve, which was continuous with the endo-
cardium, had slightly thicker connective tissue (approxi-




Biologic valve replacement has been applied in cardiac
surgery for more than 30 years. Many bioprosthetic valves
have shown excellent hemodynamic profiles, and unlike
their mechanical counterparts, they do not require perma-
nent anticoagulation.2-4 However, the endurance of biologic
tissue after placement is still a significant problem, with
only some improvement over the last decades.16,17 The
relatively short durability of bioprosthetic valves limits their
application to patients with either a contraindication to
anticoagulation (ie, during pregnancy) or to an elderly age
group with a low likelihood for reoperation.2-4,18 The mech-
anisms by which biologic valves degrade are considered
multifactorial, with involvement of immunologic rejection,
mechanical wear out, calcification, and enzymatic digestion,
with subsequent loss of the original histologic integrity.19-21
This work shows that the SIS valve provides substantial
improvement in many aspects associated with early tissue
remodeling, as well as a lack of significant immunologic
rejection, which is frequently assessed by histology,22 sug-
gesting prolonged graft survival. In concurrence with pre-
vious work with SIS material, we found no gross histologic
evidence of immunologic rejection.6-13,23 This is most likely
due to the lack of antigens, as well as the histologic remod-
eling of the SIS material, which leads to the expression of
host antigens. The SIS material is predominantly composed
of porcine extracellular matrix macromolecules, which are
477.e6 The Journal of Thoracic and Cardiovascular Surgery ● Aclosely related to their human equivalent and have a low
immunogenicity.
Currently, the mechanisms of bioprosthetic valve degen-
eration are an area of great interest. A recent work by
Simionescu and associates19 investigated the influence of
bioprosthetic valve preparation during manufacturing and
whether this can influence durability in a swine model. They
described glutaraldehyde-preserving bioprosthetic valves
that failed to prevent the breakdown of glucoseaminogly-
canes and elastin-associated microfibrils. These elastin-
associated microfibrils have important mechanical functions
in addition to protecting elastin from calcification.24 Re-
cently, several attempts have been undertaken to prevent
glutaraldehyde-treated valves from calcifying. Vasudev and
coworkers25 found calcification to be slowed by iron and
magnesium supplements. In contrast, the SIS valve does not
need pretreatment with glutaraldehyde, thus avoiding early
calcification. Furthermore, the induction of early remodel-
ing of the SIS leads to a de novo synthesis of extracellular
matrix macromolecules, including elastin-associated micro-
fibrils. A comparable approach avoiding glutaraldehyde
preparation has been attempted with the SynerGraft valve
presented by O’Brien and colleagues26 as they introduced
an artificially decellularized porcine valve. However, the
application to human subjects could not keep up with the
expectations derived from the preclinical trials. Bechtel and
associates27 reported reduced immunologic response after
SynerGraft pulmonary homograft implantation; however,
this did not translate into any clinical advantage. The expe-
rience from the SynerGraft valve implied that decellulariza-
tion was effective in decreasing rejection and avoiding
calcification, without any improvement in endurance. We
hypothesize that the ability of the SIS material to become
remodeled to a certain extent might be the key point in
creating a valve replacement more similar to the native
valve, resulting in prolonged graft survival. Nevertheless,
despite promising histologic remodeling results, the pro-
gressive thickening of the SIS valves remains of serious
concern for the potential use of this material in human
cardiac valve applications. Even though the progressive
valve thickening did not impair valvular function at 12
months, as shown in the postmortem extracorporeal cycling
studies, moderate reduction of leaflet motility was evident.
It will be essential to further investigate how this will
translate into studies beyond 12 months of SIS valve im-
plantation to assess whether the thickening will lead to
functional impairment.
Adaptation to the Vessel Wall
Given the ability of the SIS tissue to remodel, we believed
that the SIS valve would be able to adapt to the expanding
vascular system. During the early stages of the experiment,
valvular coaptation was complete and paravalvular leak did
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to the vessel wall. However, once the mismatch between the
implanted valve and the PA size exceeded a certain toler-
ance, stent fracturing and significant disruption of the pros-
thetic valve occurred. In retrospect, these findings might be
explained by the rapid somatic growth of the swine and the
constraints of the stent frame. The SIS valve used in this
study included metal square stents, which cannot expand
beyond physical limits. Once the valve stent was implanted
in the right PA not exceeding the frame constraints, as
documented in the third pig killed at 12 months, the valve
was not impaired. Therefore, the vessel adaptation of the
valve appears limited by the metallic stent and not by the
SIS leaflets. This problem will have to be addressed through
either modification or removal of the metal stent, resulting
in a device with a flexible diameter in future experiments.
Low-Profile Percutaneous Valve Placement
Percutaneous catheter-based systems for the treatment of
valvular heart disease have been studied in animal models
for several years.28 The major advantage of this approach is
that it does not require surgical intervention. Nevertheless,
surgical procedures still make up the vast majority of valve
replacements.29 Recently, Bonhoeffer and coworkers,30 us-
ing a bovine jugular vein valve mounted within a stent,
performed the first human percutaneous implantation of an
artificial valve in children with right ventricle–pulmonary
prosthetic conduits. In addition, Cribier and colleagues31
described one case report with a successful percutaneous
valve replacement in a 57-year-old man. The current im-
plantation procedures are based on large delivery systems.
Bonhoeffer and coworkers30 used 22F catheters for pulmo-
nary valve replacement, and Cribier and colleagues31 used
24F catheters for aortic valve placement. In this experiment
8F catheter delivery systems were used. We hypothesize
that further improvement making the percutaneous place-
ment procedure even less invasive might substantiate the
potential of this upcoming technology.
Conclusion
The SIS valve has the potential for combined graft longevity
without the need for anticoagulation or immunosuppression.
Histologic remodeling of the valve tissue provides a re-
placement comparable with the native valve. Furthermore,
the SIS valve can be placed percutaneously by using a
low-profile catheter delivery system.
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Ruiz et al Evolving TechnologyFigure E1. A-C, CD3 antibody staining: A, CD3 control, 200x. Solid arrow outlines lymphoid follicle. Dotted arrow
outlines T-cell rich region that stains strongly with CD3 antibody. B, CD3 on SIS leaflet at 6 months, 200x. Stellate
and spindle-shaped host stromal cells have low-grade staining (considered nonspecific). Cells with morphology
of lymphocytes (arrows) did not stain. C, CD3 on SIS leaflet at 6 months, 400x. Stellate and spindle-shaped host
stromal cells have low-grade staining (considered nonspecific). Cells with morphology of lymphocytes (arrows)
did not stain. D-F, MAC 387 (myeloid) antibody staining: D, MAC 387 control, 200x. A, Arteriole; double arrow,
lymphoid sheath without staining. Large dark-staining cells (singlehead arrow) are positive macrophages. E, MAC
387 on SIS leaflet at 6 months, 200x. Stellate (dotted arrow) and spindle-shaped (solid arrows) host stromal cells
have no staining. Round-shaped cells that could represent macrophages were very rare and did not stain. F, MAC
387 on SIS leaflet at 6 months, 400x. Stellate and spindle-shaped host stromal cells have no staining. Round-shaped
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